FDA fast-tracks biosimilar approvals, automatically allowing drug substitutions
S. 1954 — Biosimilar Red Tape Elimination Act · Filed by Mike Lee (R-UT) · 5 cosponsors · Introduced Jun 4, 2025 · Reported out
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill streamlines FDA approval for biosimilar drugs (cheaper copies of expensive biologic medicines) by eliminating the requirement that biosimilars prove they are 'interchangeable' with the original drug before being approved. Instead, all biosimilars approved under the new standard are automatically deemed interchangeable upon licensure, removing a regulatory hurdle that has delayed patient access to lower-cost alternatives. The bill preserves existing exclusivity periods for biosimilars already approved under the old rules.
Why we flagged it
The bill's core function is to simplify FDA approval pathways for biosimilar drugs by removing the interchangeability determination step and automatically deeming approved biosimilars interchangeable. This is a deregulatory measure that accelerates market entry for generic biologics.
What the text implies
- Automatic interchangeability may reduce pharmacist discretion and physician control over substitution decisions, potentially affecting clinical outcomes if biosimilars have subtle differences from reference products that emerge post-approval.
- The 60-day transition period creates a narrow window during which biosimilars approved before enactment must comply with new rules, potentially disrupting existing market arrangements and exclusivity agreements.
The full analysis lists 4 implications of this text.
Who stands to gain
biosimilar manufacturers; generic drug companies; pharmacy benefit managers (PBMs)